{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:51:44Z","timestamp":1794091904188,"version":"4.8.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41582-025-01115-5","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:16:20Z","timestamp":1753262180000},"page":"432-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Advancing multiple sclerosis management in older adults"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-5864","authenticated-orcid":false,"given":"Eva M. M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-7549","authenticated-orcid":false,"given":"Timothy","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace J.","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-8727","authenticated-orcid":false,"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5799-6457","authenticated-orcid":false,"given":"Anna","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-5359","authenticated-orcid":false,"given":"Mar","family":"Tintore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the International Advisory Committee Clinical Trials in MS Workshop on Ageing and MS members","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Amezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina J.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Banwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce F.","family":"Bebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Corboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valina Lynn","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Hawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Lebrun","family":"Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred D.","family":"Lublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Mowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pontillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zaratin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","volume":"15","author":"CB Vaughn","year":"2019","unstructured":"Vaughn, C. B. et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat. Rev. Neurol. 15, 329\u2013342 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1115_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/jnnp-2022-329049","volume":"93","author":"L Prosperini","year":"2022","unstructured":"Prosperini, L. et al. Shift of multiple sclerosis onset towards older age. J. Neurol. Neurosurg. Psychiatry 93, 1137\u20131139 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1115_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ana.26843","volume":"95","author":"S Knowles","year":"2024","unstructured":"Knowles, S. et al. Comparing the pathology, clinical, and demographic characteristics of younger and older-onset multiple sclerosis. Ann. Neurol. 95, 471\u2013486 (2024).","journal-title":"Ann. Neurol."},{"key":"1115_CR4","doi-asserted-by":"publisher","first-page":"104506","DOI":"10.1016\/j.msard.2023.104506","volume":"70","author":"J Moura","year":"2023","unstructured":"Moura, J. et al. Characterization of a late-onset multiple sclerosis Portuguese cohort. Mult. Scler. Relat. Disord. 70, 104506 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR5","doi-asserted-by":"publisher","first-page":"102816","DOI":"10.1016\/j.msard.2021.102816","volume":"50","author":"A Naseri","year":"2021","unstructured":"Naseri, A., Nasiri, E., Sahraian, M. A., Daneshvar, S. & Talebi, M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult. Scler. Relat. Disord. 50, 102816 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","volume":"22","author":"JS Graves","year":"2023","unstructured":"Graves, J. S. et al. Ageing and multiple sclerosis. Lancet Neurol. 22, 66\u201377 (2023).","journal-title":"Lancet Neurol."},{"key":"1115_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1115_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2023-332883","volume":"95","author":"YC Foong","year":"2024","unstructured":"Foong, Y. C. et al. Comparing ocrelizumab to interferon\/glatiramer acetate in people with multiple sclerosis over age 60. J. Neurol. Neurosurg. Psychiatry 95, 767\u2013774 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1115_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M. & Bielekova, B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front. Neurol. 8, 577 (2017).","journal-title":"Front. Neurol."},{"key":"1115_CR10","doi-asserted-by":"publisher","first-page":"100470","DOI":"10.1016\/j.bbih.2022.100470","volume":"22","author":"JS Brand","year":"2022","unstructured":"Brand, J. S., Smith, K. A., Piehl, F., Olsson, T. & Montgomery, S. Risk of serious infections in multiple sclerosis patients by disease course and disability status: results from a Swedish register-based study. Brain Behav., Immun. Health 22, 100470 (2022).","journal-title":"Brain Behav., Immun. Health"},{"key":"1115_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.maturitas.2020.05.018","volume":"139","author":"E Rudnicka","year":"2020","unstructured":"Rudnicka, E. et al. The World Health Organization (WHO) approach to healthy ageing. Maturitas 139, 6\u201311 (2020).","journal-title":"Maturitas"},{"key":"1115_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43587-021-00048-0","volume":"1","author":"WJ Jagust","year":"2021","unstructured":"Jagust, W. J. Youthfulness begins in youth. Nat. Aging 1, 239\u2013240 (2021).","journal-title":"Nat. Aging"},{"key":"1115_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ana.25592","volume":"86","author":"KM Krysko","year":"2019","unstructured":"Krysko, K. M. et al. Telomere length is associated with disability progression in multiple sclerosis. Ann. Neurol. 86, 671\u2013682 (2019).","journal-title":"Ann. Neurol."},{"key":"1115_CR14","doi-asserted-by":"publisher","first-page":"105607","DOI":"10.1016\/j.msard.2024.105607","volume":"86","author":"M Zhong","year":"2024","unstructured":"Zhong, M. et al. Leukocyte telomere length in multiple sclerosis: relationship between disability severity and pregnancy history. Mult. Scler. Relat. Disord. 86, 105607 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","volume":"597","author":"M Absinta","year":"2021","unstructured":"Absinta, M. et al. A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis. Nature 597, 709\u2013714 (2021).","journal-title":"Nature"},{"key":"1115_CR16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3390\/cells11121966","volume":"11","author":"K-D Wagner","year":"2022","unstructured":"Wagner, K.-D. & Wagner, N. The senescence markers p16INK4A, p14ARF\/p19ARF, and p21 in organ development and homeostasis. Cells 11, 1966 (2022).","journal-title":"Cells"},{"key":"1115_CR17","doi-asserted-by":"publisher","first-page":"105498","DOI":"10.1016\/j.msard.2024.105498","volume":"84","author":"JH Yang","year":"2024","unstructured":"Yang, J. H., Miner, A. E., Fair, A., Kinkel, R. & Graves, J. S. Senescence marker p16INK4a expression in patients with multiple sclerosis. Mult. Scler. Relat. Disord. 84, 105498 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR18","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1212\/WNL.0000000000207489","volume":"101","author":"V Maltby","year":"2023","unstructured":"Maltby, V. et al. Evaluation of cell-specific epigenetic age acceleration in people with multiple sclerosis. Neurology 101, e679\u2013e689 (2023).","journal-title":"Neurology"},{"key":"1115_CR19","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.msard.2023.104859","volume":"77","author":"AE Miner","year":"2023","unstructured":"Miner, A. E., Yang, J. H., Kinkel, R. P. & Graves, J. S. The NHANES biological age index demonstrates accelerated aging in MS patients. Mult. Scler. Relat. Disord. 77, 104859 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.25746","volume":"88","author":"JH Cole","year":"2020","unstructured":"Cole, J. H. et al. Longitudinal assessment of multiple sclerosis with the brain-age paradigm. Ann. Neurol. 88, 93\u2013105 (2020).","journal-title":"Ann. Neurol."},{"key":"1115_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/bjophthalmol-2021-319807","volume":"107","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Retinal age gap as a predictive biomarker for mortality risk. Br. J. Ophthalmol. 107, 547\u2013554 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"1115_CR22","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s11357-023-00920-4","volume":"46","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Deep neural network-estimated age using optical coherence tomography predicts mortality. GeroScience 46, 1703\u20131711 (2024).","journal-title":"GeroScience"},{"key":"1115_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2007.01.005","volume":"123","author":"M Thewissen","year":"2007","unstructured":"Thewissen, M. et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 123, 209\u2013218 (2007).","journal-title":"Clin. Immunol."},{"key":"1115_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neubiorev.2017.01.044","volume":"75","author":"S Di Benedetto","year":"2017","unstructured":"Di Benedetto, S., M\u00fcller, L., Wenger, E., D\u00fczel, S. & Pawelec, G. Contribution of neuroinflammation and immunity to brain aging and the mitigating effects of physical and cognitive interventions. Neurosci. Biobehav. Rev. 75, 114\u2013128 (2017).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1115_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/187152711796235014","volume":"10","author":"V Pizza","year":"2011","unstructured":"Pizza, V., Agresta, A., D\u2019Acunto, C. W., Festa, M. & Capasso, A. Neuroinflamm-aging and neurodegenerative diseases: an overview. CNSNDDT 10, 621\u2013634 (2011).","journal-title":"CNSNDDT"},{"key":"1115_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","volume":"908","author":"C Franceschi","year":"2000","unstructured":"Franceschi, C. et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 908, 244\u2013254 (2000).","journal-title":"Ann. NY Acad. Sci."},{"key":"1115_CR27","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1523\/JNEUROSCI.22-07-02451.2002","volume":"22","author":"FJ Sim","year":"2002","unstructured":"Sim, F. J., Zhao, C., Penderis, J. & Franklin, R. J. M. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J. Neurosci. 22, 2451\u20132459 (2002).","journal-title":"J. Neurosci."},{"key":"1115_CR28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt, T., Antel, J., Konig, F. B., Bruck, W. & Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity | neurology. Neurology 72, 1914\u20131921 (2009).","journal-title":"Neurology"},{"key":"1115_CR29","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/WNL.0000000000004843","volume":"90","author":"JS Graves","year":"2018","unstructured":"Graves, J. S. et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology 90, e254\u2013e260 (2018).","journal-title":"Neurology"},{"key":"1115_CR30","doi-asserted-by":"publisher","first-page":"766308","DOI":"10.3389\/fneur.2021.766308","volume":"12","author":"MC Ysrraelit","year":"2021","unstructured":"Ysrraelit, M. C. & Correale, J. Impact of andropause on multiple sclerosis. Front. Neurol. 12, 766308 (2021).","journal-title":"Front. Neurol."},{"key":"1115_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4049\/jimmunol.159.1.3","volume":"159","author":"M Dalal","year":"1997","unstructured":"Dalal, M., Kim, S. & Voskuhl, R. R. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J. Immunol. 159, 3\u20136 (1997).","journal-title":"J. Immunol."},{"key":"1115_CR32","doi-asserted-by":"publisher","first-page":"103508","DOI":"10.1016\/j.msard.2022.103508","volume":"59","author":"C Diaconu","year":"2022","unstructured":"Diaconu, C. et al. Hypogonadism in men with multiple sclerosis: prevalence and clinical associations. Mult. Scler. Relat. Disord. 59, 103508 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1352458517737396","volume":"24","author":"R Bove","year":"2018","unstructured":"Bove, R. & Gilmore, W. Hormones and MS: risk factors, biomarkers, and therapeutic targets. Mult. Scler. 24, 17\u201321 (2018).","journal-title":"Mult. Scler."},{"key":"1115_CR34","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1212\/WNL.0b013e318296e98b","volume":"80","author":"JF Sumowski","year":"2013","unstructured":"Sumowski, J. F. et al. Brain reserve and cognitive reserve in multiple sclerosis. Neurology 80, 2186\u20132193 (2013).","journal-title":"Neurology"},{"key":"1115_CR35","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s00415-016-8104-5","volume":"263","author":"BM Sandroff","year":"2016","unstructured":"Sandroff, B. M., Schwartz, C. E. & DeLuca, J. Measurement and maintenance of reserve in multiple sclerosis. J. Neurol. 263, 2158\u20132169 (2016).","journal-title":"J. Neurol."},{"key":"1115_CR36","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s00415-012-6762-5","volume":"260","author":"H Vrenken","year":"2013","unstructured":"Vrenken, H. et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J. Neurol. 260, 2458\u20132471 (2013).","journal-title":"J. Neurol."},{"key":"1115_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/jnnp-2022-330613","volume":"94","author":"J Sastre-Garriga","year":"2023","unstructured":"Sastre-Garriga, J. et al. Spinal cord reserve in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 502\u2013510 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1115_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2012.08.033","volume":"323","author":"RW Motl","year":"2012","unstructured":"Motl, R. W., Dlugonski, D., Pilutti, L., Sandroff, B. & McAuley, E. Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 323, 123\u2013127 (2012).","journal-title":"J. Neurol. Sci."},{"key":"1115_CR39","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1177\/13524585241277400","volume":"30","author":"R Holtzer","year":"2024","unstructured":"Holtzer, R. et al. Brain hemodynamic responses and fall prediction in older adults with multiple sclerosis. Mult. Scler. 30, 1664\u20131673 (2024).","journal-title":"Mult. Scler."},{"key":"1115_CR40","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1177\/1352458519856847","volume":"25","author":"R Brandstadter","year":"2019","unstructured":"Brandstadter, R., Katz Sand, I. & Sumowski, J. F. Beyond rehabilitation: a prevention model of reserve and brain maintenance in multiple sclerosis. Mult. Scler. 25, 1372\u20131378 (2019).","journal-title":"Mult. Scler."},{"key":"1115_CR41","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/jcm9051326","volume":"9","author":"O Mirmosayyeb","year":"2020","unstructured":"Mirmosayyeb, O. et al. Clinical characteristics and disability progression of early- and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J. Clin. Med. 9, 1326 (2020).","journal-title":"J. Clin. Med."},{"key":"1115_CR42","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","volume":"142","author":"M Filippi","year":"2019","unstructured":"Filippi, M. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 142, 1858\u20131875 (2019).","journal-title":"Brain"},{"key":"1115_CR43","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1212\/WNL.0000000000004715","volume":"89","author":"G Arrambide","year":"2017","unstructured":"Arrambide, G. et al. Lesion topographies in multiple sclerosis diagnosis: a reappraisal. Neurology 89, 2351\u20132356 (2017).","journal-title":"Neurology"},{"key":"1115_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1148\/radiol.2231010707","volume":"223","author":"JCJ Bot","year":"2002","unstructured":"Bot, J. C. J. et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology 223, 46\u201356 (2002).","journal-title":"Radiology"},{"key":"1115_CR45","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrneurol.2016.166","volume":"12","author":"P Sati","year":"2016","unstructured":"Sati, P. et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American imaging in multiple sclerosis cooperative. Nat. Rev. Neurol. 12, 714\u2013722 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"1115_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28271","volume":"4","author":"C Lebrun-Fr\u00e9nay","year":"2021","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw. Open. 4, e2128271 (2021).","journal-title":"JAMA Netw. Open."},{"key":"1115_CR47","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/brain\/awad073","volume":"146","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay, C. et al. The radiologically isolated syndrome: revised diagnostic criteria. Brain 146, 3431\u20133443 (2023).","journal-title":"Brain"},{"key":"1115_CR48","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold, A. et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 21, 1120\u20131134 (2022).","journal-title":"Lancet Neurol."},{"key":"1115_CR49","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jamaneurol.2024.3062","volume":"81","author":"LH Hua","year":"2024","unstructured":"Hua, L. H. et al. Differential diagnosis of suspected multiple sclerosis in pediatric and late-onset populations: a review. JAMA Neurol.\u00a081,\u00a01210\u20131222\u00a0(2024).","journal-title":"JAMA Neurol."},{"key":"1115_CR50","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/healthcare11152126","volume":"11","author":"C Bakirtzis","year":"2023","unstructured":"Bakirtzis, C. et al. Secondary central nervous system demyelinating disorders in the elderly: a narrative review. Healthcare 11, 2126 (2023).","journal-title":"Healthcare"},{"key":"1115_CR51","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","volume":"22","author":"AJ Solomon","year":"2023","unstructured":"Solomon, A. J. et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 22, 750\u2013768 (2023).","journal-title":"Lancet Neurol."},{"key":"1115_CR52","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/13524585211039112","volume":"28","author":"R Butler Pagnotti","year":"2022","unstructured":"Butler Pagnotti, R., Hua, L. H. & Miller, J. B. Cognition and disease characteristics in adult onset versus late onset multiple sclerosis. Mult. Scler. 28, 933\u2013941 (2022).","journal-title":"Mult. Scler."},{"key":"1115_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","volume":"90","author":"JF Sumowski","year":"2018","unstructured":"Sumowski, J. F. et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology 90, 278\u2013288 (2018).","journal-title":"Neurology"},{"key":"1115_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200327","volume":"14","author":"LM Hancock","year":"2024","unstructured":"Hancock, L. M. et al. Comparing cognitive profiles in older adults with multiple sclerosis and alzheimer disease: more similarities than differences. Neurol. Clin. Pract. 14, e200327 (2024).","journal-title":"Neurol. Clin. Pract."},{"key":"1115_CR55","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s10072-019-03875-7","volume":"40","author":"M Branco","year":"2019","unstructured":"Branco, M. et al. Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurol. Sci. 40, 1651\u20131657 (2019).","journal-title":"Neurol. Sci."},{"key":"1115_CR56","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1007\/s11357-023-01054-3","volume":"46","author":"R Holtzer","year":"2024","unstructured":"Holtzer, R. et al. Brain control of dual-task walking can be improved in aging and neurological disease. Geroscience 46, 3169\u20133184 (2024).","journal-title":"Geroscience"},{"key":"1115_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict, R. H. B., Amato, M. P., DeLuca, J. & Geurts, J. J. G. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 19, 860\u2013871 (2020).","journal-title":"Lancet Neurol."},{"key":"1115_CR58","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1177\/1352458516679036","volume":"23","author":"S Roy","year":"2017","unstructured":"Roy, S. et al. Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Mult. Scler. 23, 1385\u20131393 (2017).","journal-title":"Mult. Scler."},{"key":"1115_CR59","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2024.2920","volume":"81","author":"A Salter","year":"2024","unstructured":"Salter, A., Lancia, S., Kowalec, K., Fitzgerald, K. C. & Marrie, R. A. Comorbidity and disease activity in multiple sclerosis. JAMA Neurol. 81, 1170\u20131177 (2024).","journal-title":"JAMA Neurol."},{"key":"1115_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie, R. A. Comorbidity in multiple sclerosis: implications for patient care. Nat. Rev. Neurol. 13, 375\u2013382 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1115_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1352458514564491","volume":"21","author":"RA Marrie","year":"2015","unstructured":"Marrie, R. A. et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult. Scler. 21, 263\u2013281 (2015).","journal-title":"Mult. Scler."},{"key":"1115_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1352458508099477","volume":"15","author":"RA Marrie","year":"2009","unstructured":"Marrie, R. A. et al. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult. Scler. 15, 385\u2013392 (2009).","journal-title":"Mult. Scler."},{"key":"1115_CR63","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1212\/WNL.0000000000004716","volume":"89","author":"K Kowalec","year":"2017","unstructured":"Kowalec, K. et al. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology 89, 2455\u20132461 (2017).","journal-title":"Neurology"},{"key":"1115_CR64","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","volume":"73","author":"L Negrotto","year":"2016","unstructured":"Negrotto, L., Farez, M. F. & Correale, J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 73, 520\u2013528 (2016).","journal-title":"JAMA Neurol."},{"key":"1115_CR65","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-023-12041-1","volume":"271","author":"A Zinganell","year":"2024","unstructured":"Zinganell, A. et al. Multiple sclerosis in the elderly: a retrospective cohort study. J. Neurol. 271, 674\u2013687 (2024).","journal-title":"J. Neurol."},{"key":"1115_CR66","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208051","volume":"102","author":"EF Mouresan","year":"2024","unstructured":"Mouresan, E. F. et al. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish nationwide study. Neurology 102, e208051 (2024).","journal-title":"Neurology"},{"key":"1115_CR67","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1177\/1352458518800815","volume":"25","author":"BL Conway","year":"2019","unstructured":"Conway, B. L. et al. Age is a critical determinant in recovery from multiple sclerosis relapses. Mult. Scler. 25, 1754\u20131763 (2019).","journal-title":"Mult. Scler."},{"key":"1115_CR68","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/brain\/awaa199","volume":"143","author":"T Chitnis","year":"2020","unstructured":"Chitnis, T. et al. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain 143, 2733\u20132741 (2020).","journal-title":"Brain"},{"key":"1115_CR69","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209574","volume":"103","author":"S Pfeuffer","year":"2024","unstructured":"Pfeuffer, S. et al. Association of clinical relapses with disease outcomes in multiple sclerosis patients older than 50\u2009years. Neurology 103, e209574 (2024).","journal-title":"Neurology"},{"key":"1115_CR70","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33, 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"1115_CR71","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.msard.2020.102724","volume":"49","author":"S Lynch","year":"2021","unstructured":"Lynch, S. et al. Disability measurement in multiple sclerosis patients 55\u2009years and older: what is the Expanded Disability Status Scale really telling clinicians? Mult. Scler. Relat. Disord. 49, 102724 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR72","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter, G. R. et al. Development of a Multiple Sclerosis Functional Composite as a clinical trial outcome measure. Brain 122, 871\u2013882 (1999).","journal-title":"Brain"},{"key":"1115_CR73","doi-asserted-by":"publisher","first-page":"570","DOI":"10.5014\/ajot.57.5.570","volume":"57","author":"K Oxford Grice","year":"2003","unstructured":"Oxford Grice, K. et al. Adult norms for a commercially available nine hole peg test for finger dexterity. Am. J. Occup. Ther. 57, 570\u2013573 (2003).","journal-title":"Am. J. Occup. Ther."},{"key":"1115_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/153944928500500102","volume":"5","author":"V Mathiowetz","year":"1985","unstructured":"Mathiowetz, V., Weber, K., Kashman, N. & Volland, G. Adult norms for the nine hole peg test of finger dexterity. Occup. Ther. J. Res. 5, 24\u201338 (1985).","journal-title":"Occup. Ther. J. Res."},{"key":"1115_CR75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/ADR-200194","volume":"4","author":"J Ryan","year":"2020","unstructured":"Ryan, J. et al. Normative data for the Symbol Digit Modalities Test in older white Australians and Americans, African-Americans, and Hispanic\/Latinos. J. Alzheimers Dis. Rep. 4, 313\u2013323 (2020).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"1115_CR76","doi-asserted-by":"publisher","first-page":"102576","DOI":"10.1016\/j.msard.2020.102576","volume":"46","author":"LB Strober","year":"2020","unstructured":"Strober, L. B. et al. Tired of not knowing what that fatigue score means? Normative data of the Modified Fatigue Impact Scale (MFIS). Mult. Scler. Relat. Disord. 46, 102576 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1115_CR77","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000616","volume":"6","author":"CJ Azevedo","year":"2019","unstructured":"Azevedo, C. J. et al. Contribution of normal aging to brain atrophy in MS. Neurol. Neuroimmunol. Neuroinflamm. 6, e616 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1115_CR78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.25150","volume":"83","author":"CJ Azevedo","year":"2018","unstructured":"Azevedo, C. J. et al. Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann. Neurol. 83, 223\u2013234 (2018).","journal-title":"Ann. Neurol."},{"key":"1115_CR79","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200269","volume":"11","author":"T-Y Lin","year":"2024","unstructured":"Lin, T.-Y. et al. Individual prognostication of disease activity and disability worsening in multiple sclerosis with retinal layer thickness z scores. Neurol. Neuroimmunol. Neuroinflamm 11, e200269 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1115_CR80","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2007.01.023","volume":"114","author":"RS Parikh","year":"2007","unstructured":"Parikh, R. S. et al. Normal age-related decay of retinal nerve fiber layer thickness. Ophthalmology 114, 921\u2013926 (2007).","journal-title":"Ophthalmology"},{"key":"1115_CR81","doi-asserted-by":"publisher","first-page":"1873581","DOI":"10.1155\/2020\/1873581","volume":"2020","author":"D Jeong","year":"2020","unstructured":"Jeong, D., Sung, K. R., Jo, Y. H. & Yun, S. Age-related physiologic thinning rate of the retinal nerve fiber layer in different levels of myopia. J. Ophthalmol. 2020, 1873581 (2020).","journal-title":"J. Ophthalmol."},{"key":"1115_CR82","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/acn3.51969","volume":"11","author":"A Abdelhak","year":"2024","unstructured":"Abdelhak, A. et al. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Ann. Clin. Transl. Neurol. 11, 477\u2013485 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1115_CR83","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","volume":"9","author":"L Vermunt","year":"2022","unstructured":"Vermunt, L. et al. Age\u2010 and disease\u2010specific reference values for neurofilament light presented in an online interactive support interface. Ann. Clin. Transl. Neurol. 9, 1832\u20131837 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1115_CR84","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257 (2022).","journal-title":"Lancet Neurol."},{"key":"1115_CR85","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S1474-4422(23)00210-7","volume":"22","author":"A Abdelhak","year":"2023","unstructured":"Abdelhak, A. et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 22, 826\u2013833 (2023).","journal-title":"Lancet Neurol."},{"key":"1115_CR86","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1177\/13524585241269216","volume":"30","author":"A Abdelhak","year":"2024","unstructured":"Abdelhak, A. et al. ECTRIMS 2024\u2014late breaking oral presentations. Mult. Scler. 30, 1138\u20131147 (2024).","journal-title":"Mult. Scler."},{"key":"1115_CR87","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick, R. A. et al. Natalizumab plus interferon \u03b2-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911\u2013923 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1115_CR88","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899\u2013910 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1115_CR89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387\u2013401 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1115_CR90","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402\u2013415 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1115_CR91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon \u03b2-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1115_CR92","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","volume":"74","author":"H Tremlett","year":"2010","unstructured":"Tremlett, H., Zhao, Y., Rieckmann, P. & Hutchinson, M. New perspectives in the natural history of multiple sclerosis. Neurology 74, 2004\u20132015 (2010).","journal-title":"Neurology"},{"key":"1115_CR93","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown, J. W. L. et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321, 175\u2013187 (2019).","journal-title":"JAMA"},{"key":"1115_CR94","doi-asserted-by":"publisher","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron, G. et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front. Neurol. 14, 1197212 (2023).","journal-title":"Front. Neurol."},{"key":"1115_CR95","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","volume":"44","author":"T Kalincik","year":"2015","unstructured":"Kalincik, T. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44, 199\u2013214 (2015).","journal-title":"Neuroepidemiology"},{"key":"1115_CR96","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/jnnp-2022-330887","volume":"94","author":"EM Strijbis","year":"2023","unstructured":"Strijbis, E. M. et al. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 792\u2013799 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1115_CR97","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/13524585241272938","volume":"30","author":"EM Coerver","year":"2024","unstructured":"Coerver, E. M. et al. Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations. Mult. Scler. 30, 1296\u20131308 (2024).","journal-title":"Mult. Scler."},{"key":"1115_CR98","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/brain\/awaa251","volume":"143","author":"MP Amato","year":"2020","unstructured":"Amato, M. P. et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143, 3013\u20133024 (2020).","journal-title":"Brain"},{"key":"1115_CR99","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s00415-023-12152-9","volume":"271","author":"L Lorefice","year":"2024","unstructured":"Lorefice, L. et al. Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS registry. J. Neurol. 271, 1630\u20131637 (2024).","journal-title":"J. Neurol."},{"key":"1115_CR100","doi-asserted-by":"publisher","first-page":"829331","DOI":"10.3389\/fneur.2022.829331","volume":"13","author":"MC Buscarinu","year":"2022","unstructured":"Buscarinu, M. C. et al. Late-onset MS: disease course and safety-efficacy of DMTS. Front. Neurol. 13, 829331 (2022).","journal-title":"Front. Neurol."},{"key":"1115_CR101","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/13524585221074010","volume":"28","author":"M Moccia","year":"2022","unstructured":"Moccia, M. et al. Emergency medical care for multiple sclerosis: a five-year population study in the Campania region (South Italy). Mult. Scler. 28, 597\u2013607 (2022).","journal-title":"Mult. Scler."},{"key":"1115_CR102","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould, A., Li, B. H., Smith, J. B. & Xu, S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol. Neuroimmunol. Neuroinflamm. 11, e200211 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1115_CR103","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ana.27026","volume":"96","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Hospital-treated infections and risk of disability worsening in multiple sclerosis. Ann. Neurol.\u00a096,\u00a0694\u2013703\u00a0(2024).","journal-title":"Ann. Neurol."},{"key":"1115_CR104","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/13524585251318513","volume":"31","author":"R Carvajal","year":"2025","unstructured":"Carvajal, R. et al. Vaccination in multiple sclerosis: tackling challenges and paving the way for effective immunization. Mult. Scler. 31, 754\u2013763 (2025).","journal-title":"Mult. Scler."},{"key":"1115_CR105","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5694\/mja2.51012","volume":"214","author":"C Nesbitt","year":"2021","unstructured":"Nesbitt, C. et al. Vaccinations in patients with multiple sclerosis: review and recommendations. Med. J. Aust. 214, 350\u2013354 (2021).","journal-title":"Med. J. Aust."},{"key":"1115_CR106","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/1352458520923945","volume":"27","author":"X Ayrignac","year":"2021","unstructured":"Ayrignac, X. et al. Frailty in ageing persons with multiple sclerosis. Mult. Scler. 27, 613\u2013620 (2021).","journal-title":"Mult. Scler."},{"key":"1115_CR107","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41577-019-0177-9","volume":"19","author":"NA Duggal","year":"2019","unstructured":"Duggal, N. A., Niemiro, G., Harridge, S. D. R., Simpson, R. J. & Lord, J. M. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat. Rev. Immunol. 19, 563\u2013572 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1115_CR108","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/13524585221079200","volume":"28","author":"M Riemenschneider","year":"2022","unstructured":"Riemenschneider, M. et al. Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES). Mult. Scler. 28, 1620\u20131629 (2022).","journal-title":"Mult. Scler."},{"key":"1115_CR109","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/jnnp-2024-333460","volume":"95","author":"MA Rocca","year":"2024","unstructured":"Rocca, M. A. et al. Cognitive rehabilitation effects on grey matter volume and Go\u2013NoGo activity in progressive multiple sclerosis: results from the CogEx trial. J. Neurol. Neurosurg. Psychiatry 95, 1139\u20131149 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1115_CR110","doi-asserted-by":"publisher","first-page":"1286122","DOI":"10.3389\/fneur.2023.1286122","volume":"14","author":"G Giovannoni","year":"2024","unstructured":"Giovannoni, G. et al. MS care: integrating advanced therapies and holistic management. Front. Neurol. 14, 1286122 (2024).","journal-title":"Front. Neurol."},{"key":"1115_CR111","unstructured":"Multiple Sclerosis International Federation. Diagnosis of MS\u2014barriers to accessing rehabilitation therapies. Atlas of MS 3rd edn https:\/\/www.atlasofms.org\/chart\/united-kingdom\/symptom-management-and-rehabilitation\/barriers-to-accessing-rehabilitation-therapies."},{"key":"1115_CR112","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.jaging.2020.100872","volume":"54","author":"EV Richardson","year":"2020","unstructured":"Richardson, E. V. & Motl, R. W. The experience and meaning of aging with multiple sclerosis: an existential phenomenological approach. J. Aging Stud. 54, 100872 (2020).","journal-title":"J. Aging Stud."},{"key":"1115_CR113","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1177\/13524585231189677","volume":"29","author":"RA Marrie","year":"2023","unstructured":"Marrie, R. A. et al. Enhancing diversity of clinical trial populations in multiple sclerosis. Mult. Scler. 29, 1174\u20131185 (2023).","journal-title":"Mult. Scler."},{"key":"1115_CR114","doi-asserted-by":"publisher","first-page":"718942","DOI":"10.3389\/fendo.2021.718942","volume":"12","author":"I Mohammed","year":"2021","unstructured":"Mohammed, I., Hollenberg, M. D., Ding, H. & Triggle, C. R. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front. Endocrinol. 12, 718942 (2021).","journal-title":"Front. Endocrinol."},{"key":"1115_CR115","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","volume":"25","author":"B Neumann","year":"2019","unstructured":"Neumann, B. et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell 25, 473\u2013485 (2019).","journal-title":"Cell Stem Cell"},{"key":"1115_CR116","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/08923973.2015.1028074","volume":"37","author":"G Azizi","year":"2015","unstructured":"Azizi, G., Goudarzvand, M., Afraei, S., Sedaghat, R. & Mirshafiey, A. Therapeutic effects of dasatinib in mouse model of multiple sclerosis. Immunopharmacol. Immunotoxicol. 37, 287\u2013294 (2015).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"1115_CR117","doi-asserted-by":"publisher","first-page":"109647","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek, M. A., Kandil, E. A., El Sayed, N. S., Sayed, H. M. & Rabie, M. A. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int. Immunopharmacol. 115, 109647 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1115_CR118","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/ene.14705","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh, G. et al. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score. Eur. J. Neurol. 28, 1609\u20131616 (2021).","journal-title":"Eur. J. Neurol."},{"key":"1115_CR119","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy, J. R. et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 22, 568\u2013577 (2023).","journal-title":"Lancet Neurol."},{"key":"1115_CR120","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","volume":"81","author":"G Jouvenot","year":"2024","unstructured":"Jouvenot, G. et al. High-efficacy therapy discontinuation vs continuation in patients 50\u2009years and older with nonactive MS. JAMA Neurol.\u00a081,\u00a0490\u2013498\u00a0(2024).","journal-title":"JAMA Neurol."},{"key":"1115_CR121","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40263-025-01164-w","volume":"39","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller, J. et al. Treatment de-escalation in relapsing-remitting multiple sclerosis: an observational study. CNS Drugs 39, 403\u2013416 (2025).","journal-title":"CNS Drugs"},{"key":"1115_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2008-7","volume":"15","author":"S Afshar","year":"2015","unstructured":"Afshar, S., Roderick, P. J., Kowal, P., Dimitrov, B. D. & Hill, A. G. Multimorbidity and the inequalities of global ageing: a cross-sectional study of 28 countries using the World Health Surveys. BMC Public. Health 15, 776 (2015).","journal-title":"BMC Public. Health"},{"key":"1115_CR123","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1177\/1352458520963880","volume":"27","author":"RA Marrie","year":"2021","unstructured":"Marrie, R. A. et al. Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. Mult. Scler. 27, 1411\u20131420 (2021).","journal-title":"Mult. Scler."},{"key":"1115_CR124","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2522\/ptj.20100072","volume":"90","author":"M Finlayson","year":"2010","unstructured":"Finlayson, M., Plow, M. & Cho, C. Use of physical therapy services among middle-aged and older adults with multiple sclerosis. Phys. Ther. 90, 1607\u20131618 (2010).","journal-title":"Phys. Ther."},{"key":"1115_CR125","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1177\/1352458519884244","volume":"26","author":"F Boesen","year":"2020","unstructured":"Boesen, F. et al. Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term\u2014the Danish MS hospitals rehabilitation study. Mult. Scler. 26, 1953\u20131957 (2020).","journal-title":"Mult. Scler."},{"key":"1115_CR126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/14737175.2013.865873","volume":"13","author":"P Clavelou","year":"2013","unstructured":"Clavelou, P. Can we optimize our teams? Multidisciplinary care for multiple sclerosis. Expert. Rev. Neurother. 13, 39\u201344 (2013).","journal-title":"Expert. Rev. Neurother."},{"key":"1115_CR127","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4236\/jbise.2022.1511023","volume":"15","author":"FP Perez","year":"2022","unstructured":"Perez, F. P., Perez, C. A. & Chumbiauca, M. N. Insights into the social determinants of health in older adults. J. Biomed. Sci. Eng. 15, 261\u2013268 (2022).","journal-title":"J. Biomed. Sci. Eng."},{"key":"1115_CR128","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jamaneurol.2021.3416","volume":"78","author":"L Amezcua","year":"2021","unstructured":"Amezcua, L., Rivera, V. M., Vazquez, T. C., Baezconde-Garbanati, L. & Langer-Gould, A. Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: a review. JAMA Neurol. 78, 1515\u20131524 (2021).","journal-title":"JAMA Neurol."},{"key":"1115_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-2986-0","volume":"18","author":"NP Gordon","year":"2018","unstructured":"Gordon, N. P. & Hornbrook, M. C. Older adults\u2019 readiness to engage with eHealth patient education and self-care resources: a cross-sectional survey. BMC Health Serv. Res. 18, 220 (2018).","journal-title":"BMC Health Serv. Res."},{"key":"1115_CR130","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/13524585231189670","volume":"29","author":"M Finlayson","year":"2023","unstructured":"Finlayson, M., Al-Mashita, L. & Sandhu, R. Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: a scoping review. Mult. Scler. 29, 1149\u20131157 (2023).","journal-title":"Mult. Scler."},{"key":"1115_CR131","first-page":"850","volume":"51","author":"K Rasova","year":"2015","unstructured":"Rasova, K. et al. Physical therapy provision in multiple sclerosis across Europe: a regional lottery? Eur. J. Phys. Rehabil. Med. 51, 850\u2013852 (2015).","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"1115_CR132","unstructured":"European Medicines Agency. Regulatory science strategy. EMA https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/regulatory-science-strategy (2020)."},{"key":"1115_CR133","unstructured":"United States Department of Health and Human Services, United States Food and Drug Administration, Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Enhancing the diversity of clinical trial populations: eligibility criteria, enrollment practices, and trial designs. Digital Collections\u2014National Library of Medicine https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918249008406676-pdf (2020)."},{"key":"1115_CR134","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/13524585231221938","volume":"30","author":"J Hirt","year":"2024","unstructured":"Hirt, J. et al. Use of pragmatic randomized trials in multiple sclerosis: a systematic overview. Mult. Scler. 30, 463\u2013478 (2024).","journal-title":"Mult. Scler."},{"key":"1115_CR135","unstructured":"US Food & Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input (2020)."},{"key":"1115_CR136","doi-asserted-by":"publisher","first-page":"1407257","DOI":"10.3389\/fneur.2024.1407257","volume":"15","author":"P Zaratin","year":"2024","unstructured":"Zaratin, P. et al. The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care\u2014updates at the 2023 plenary event. Front. Neurol. 15, 1407257 (2024).","journal-title":"Front. Neurol."},{"key":"1115_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05849-7","volume":"22","author":"DH Bodicoat","year":"2021","unstructured":"Bodicoat, D. H. et al. Promoting inclusion in clinical trials\u2014a rapid review of the literature and recommendations for action. Trials 22, 880 (2021).","journal-title":"Trials"},{"key":"1115_CR138","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/135245850000600411","volume":"6","author":"M Kaufman","year":"2000","unstructured":"Kaufman, M., Moyer, D. & Norton, J. The significant change for the timed 25-foot walk in the Multiple Sclerosis Functional Composite. Mult. Scler. 6, 286\u2013290 (2000).","journal-title":"Mult. Scler."},{"key":"1115_CR139","first-page":"20143085","volume":"282","author":"AK Simon","year":"2015","unstructured":"Simon, A. K., Hollander, G. A. & McMichael, A. Evolution of the immune system in humans from infancy to old age. Proc. Biol. Sci. 282, 20143085 (2015).","journal-title":"Proc. Biol. Sci."},{"key":"1115_CR140","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2011.10.016","volume":"129","author":"MK Tulic","year":"2012","unstructured":"Tulic, M. K. et al. Changes in thymic regulatory T-cell maturation from birth to puberty: differences in atopic children. J. Allergy Clin. Immunol. 129, 199\u2013206 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1115_CR141","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.smim.2012.09.001","volume":"24","author":"J Nikolich-\u017dugich","year":"2012","unstructured":"Nikolich-\u017dugich, J. The aging immune system: challenges for the 21st century. Semin. Immunol. 24, 301\u2013302 (2012).","journal-title":"Semin. Immunol."},{"key":"1115_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07053-9","volume":"9","author":"J Smolders","year":"2018","unstructured":"Smolders, J. et al. Tissue-resident memory T cells populate the human brain. Nat. Commun. 9, 4593 (2018).","journal-title":"Nat. Commun."},{"key":"1115_CR143","doi-asserted-by":"publisher","first-page":"A479","DOI":"10.1016\/j.autrev.2011.11.022","volume":"11","author":"S Oertelt-Prigione","year":"2012","unstructured":"Oertelt-Prigione, S. The influence of sex and gender on the immune response. Autoimmun. Rev. 11, A479\u2013A485 (2012).","journal-title":"Autoimmun. Rev."},{"key":"1115_CR144","doi-asserted-by":"crossref","unstructured":"Coker, M. O. & Madan, J. C. in The Developing Microbiome Ch. 3 (ed. Claud, E. C.) 43\u201366 (Academic, 2020).","DOI":"10.1016\/B978-0-12-820602-7.00003-9"},{"key":"1115_CR145","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","volume":"32","author":"F Schweitzer","year":"2019","unstructured":"Schweitzer, F. et al. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Curr. Opin. Neurol. 32, 305\u2013312 (2019).","journal-title":"Curr. Opin. Neurol."},{"key":"1115_CR146","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front. Immunol. 8, 1960 (2018).","journal-title":"Front. Immunol."},{"key":"1115_CR147","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich, J. The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol. 19, 10\u201319 (2018).","journal-title":"Nat. Immunol."},{"key":"1115_CR148","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.4049\/jimmunol.1401174","volume":"193","author":"J Nikolich-\u017dugich","year":"2014","unstructured":"Nikolich-\u017dugich, J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J. Immunol. 193, 2622\u20132629 (2014).","journal-title":"J. Immunol."},{"key":"1115_CR149","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bbi.2022.10.019","volume":"107","author":"GA Noppert","year":"2023","unstructured":"Noppert, G. A., Stebbins, R. C., Dowd, J. B. & Aiello, A. E. Socioeconomic and race\/ethnic differences in immunosenescence: evidence from the health and retirement study. Brain, Behav., Immun. 107, 361\u2013368 (2023).","journal-title":"Brain, Behav., Immun."},{"key":"1115_CR150","doi-asserted-by":"publisher","first-page":"1272118","DOI":"10.3389\/fragi.2023.1272118","volume":"4","author":"A Calabr\u00f2","year":"2023","unstructured":"Calabr\u00f2, A., Accardi, G., Aiello, A., Caruso, C. & Candore, G. Sex and gender affect immune aging. Front. Aging 4, 1272118 (2023).","journal-title":"Front. Aging"},{"key":"1115_CR151","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-024-03040-8","volume":"21","author":"C Rodriguez-Mogeda","year":"2024","unstructured":"Rodriguez-Mogeda, C. et al. The role of CD56bright NK cells in neurodegenerative disorders. J. Neuroinflamm. 21, 48 (2024).","journal-title":"J. Neuroinflamm."},{"key":"1115_CR152","first-page":"483","volume":"61","author":"HI Su","year":"2009","unstructured":"Su, H. I. & Freeman, E. W. Hormone changes associated with the menopausal transition. Minerva Ginecol. 61, 483\u2013489 (2009).","journal-title":"Minerva Ginecol."},{"key":"1115_CR153","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.4103\/2230-8210.123552","volume":"17","author":"P Singh","year":"2013","unstructured":"Singh, P. Andropause: current concepts. Indian. J. Endocrinol. Metab. 17, S621\u2013S629 (2013).","journal-title":"Indian. J. Endocrinol. Metab."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01115-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01115-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:13:45Z","timestamp":1757279625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01115-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":153,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01115-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"16 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.v.d.W. has received unrestricted research grants from Biogen, Merck and Novartis; and has served on advisory boards for Biogen, Merck, Novartis and Roche, and received speaker\u2019s honoraria and travel support from these companies. E.M.M.S. has received speaker fees from Merck and Novartis. F.Br. has received travel support from Biogen and Novartis. T.C. has received travel support from the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis and Sanofi. J.G. has served as a consultant for Google and on concluded advisory boards for Horizon. W.J.B. has received speaker honoraria and\/or acted as a consultant for AstraZeneca, Biogen, Merck, Neuraxpharm, Novartis, Roche, Sandoz and Sanofi. H.B. declares that his institute has received compensation for advisory board or lecture fees from Biogen, Merck, Novartis, Roche and UCB Pharma; and his institute receives research funding from Biogen, Merck, Novartis and Roche. R.A.M is a co-investigator on studies that have received funding from Biogen, the Pfizer Foundation and Roche Canada. L.H.H. has served as a consultant to Alexion, EMD Serono, Genentech, Genzyme, Horizon, Novartis and TG Therapeutics; has served on scientific advisory boards for EMD Serono, Genentech and Novartis; has received non-promotional speaker honoraria from Genzyme and TG Therapeutics; and has received research funding paid directly to her institute from Biogen and Genentech. M.T. has received compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen, Genzyme, Immunic Therapeutics, Janssen, Merck\u2013Serono, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals and Viela Bio; and has served on Data Safety Monitoring Boards for Parexel and UCB Biopharma, and on the Relapse Adjudication Committee for Imcyse. X.M.\u2019s institution has received compensation for lecture honoraria and travel expenses, participation in scientific meetings, clinical trial steering committee membership or clinical advisory board participation from AbbVie, Actelion, Alexion, Bial, Biogen, Bristol\u00a0Myers Squibb (Celgene), EMD Serono, Genzyme, Immunic Therapeutics, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Neuraxpharm, Novartis, Peervoice, Roche, Samsung-Biosys, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics and Excemed. P.A.C. has served on advisory boards for Eli Lilly and Novartis, and is principal investigator on a research grant from Genentech. F.Ba. is a Steering Committee or Data Safety Monitoring Board member for Biogen, Eisai, Merck and Prothena, and is an advisory board member for Alzheimer Europe, Combinostics and Scottish Brain Sciences; has been a consultant for Bracco, Celltrion, Merck, Roche, and Rewind Therapeutics; has research agreements with Alzheimer\u2019s Disease Data Initiative, Biogen, GE Healthcare, Merck and Roche; and is a co-founder and shareholder of Queen Square Analytics. A.L. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}